Perspective Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Perspective Therapeutics (CATX).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

13Buy

2Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$12Upside to Avg. PT+969.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 26, 2026	RBC Capital	Leonid Timashev	Downgrade	Outperform→Sector Perform	$14→$4
Oct 7, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$14
Sep 18, 2026	William Blair	Andy Hsieh	Initiate	Outperform	—
Sep 15, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$11
Aug 14, 2026	B of A Securities	Alec Stranahan	PT Cut	Neutral	$6→$5
Aug 11, 2026	Piper Sandler	Biren Amin	PT Cut	Overweight	$16→$14
May 5, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Apr 20, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Mar 23, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$12→$13
Mar 18, 2026	B. Riley Securities	Yuan Zhi	PT Raise	Buy	$11→$13
Mar 18, 2026	UBS	David Dai	PT Raise	Buy	$7→$8
Mar 18, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Mar 17, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$18→$14
Mar 17, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$14
Feb 19, 2026	Piper Sandler	Biren Amin	Initiate	Overweight	$16
Jan 30, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$10→$12
Jan 30, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Jan 13, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$14
Nov 24, 2025	Truist Securities	Gregory Renza	Assumes	Buy	$8→$12

Analyst Ratings News

PRO
RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4

RBC Capital analyst Leonid Timashev downgrades Perspective Therapeutics (AMEX:CATX) from Outperform to Sector Perform and lowers the price target from $14 to $4.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.

Benzinga Newsdesk

This $3 Biotech Could Be Worth $11.45, Analyst Says

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.

Vandana Singh

PRO
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.

Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.

Benzinga Newsdesk

Perspective Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Perspective Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

This $3 Biotech Could Be Worth $11.45, Analyst Says

PRO
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

People Also Watch

People Also Watch

Perspective Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Perspective Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4

PROBTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

This $3 Biotech Could Be Worth $11.45, Analyst Says

PROWilliam Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

PROWedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

PROBMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

People Also Watch

People Also Watch

PRO
RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

PRO
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11